February 14th 2025
Your daily dose of the clinical news you may have missed.
February 3rd 2025
Researchers found that COVID-19 had a higher long-term mortality than influenza and RSV in veterans—underscoring vaccination’s vital role.
January 30th 2025
The study of S-337395 showed an 88.9% reduction in RSV viral load and symptom improvement in the highest dose group, with no severe adverse events reported.
October 29th 2024
Preliminary phase 1 data showed that RSV neutralizing antibodies for non-adjuvanted SCB-1019 matched GSK’s AS01E-adjuvanted RSV vaccine, Arexvy.
October 23rd 2024
Pfizer announced the FDA approval on October 22 that makes Abrysvo now the RSV immunization with the broadest indication for adults, the company said.
